drugset / Trial / NCT06436781

Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population

NCT06436781 ↗

Phase 3 Completed 33 enrolled RDC Clinical Pty Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on post exercise inflammation, exercise recovery and muscle fatigue and pain in an otherwise healthy population of adults 18-65 years old over 10 weeks with 8 weeks of supplementation. This is PART A of the study.

Timeline

Start
2024-09-12
Primary completion
2025-05-23
Completion
2025-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Maolactin Protein / enzyme biologic 500 mg —